Novavax (NVAX) Profit Jumps on Milestone

05:13pm, Wednesday, 06'th Aug 2025
Novavax (NVAX) Profit Jumps on Milestone
Novavax, Inc. (NASDAQ:NVAX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants James Patrick Kelly - Executive VP, CFO & Treasurer John Charles Jacobs - President, CEO &
Novavax (NVAX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to earnings of $0.99 per share a year ago.
Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment related to U.S. approval of its COVID-19 vaccine in May.
Total revenue of $239 million in the second quarter of 2025 Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval t
In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.
GAITHERSBURG, Md. , July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single in
In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The latest trading day saw Novavax (NVAX) settling at $6.36, representing a -2.15% change from its previous close.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE